**Name of Journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 28237**

**Manuscript Type: Meta-Analysis**

***PNPLA3* polymorphism increases risk and severity of chronic hepatitis C liver disease**

Salameh H *et al.* HCV disease

**Habeeb Salameh, Maen Masadeh, Muhannad Al Hanayneh, Vincent Petros, Matthew Maslonka, Arjun Nanda, Ashwani K Singal**

**Habeeb Salameh, Muhannad Al Hanayneh** Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Texas Medical Branch, Galveston, TX 77555, United States

**Maen Masadeh**, Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Iowa, Iowa City, IA 52242, United States

**Vincent Petros, Matthew Maslonka** Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555,United States

**Arjun Nanda, Ashwani K Singal** Division of Gastroenterology and Hepatology, University of Alabama, Birmingham, AL 35294, United States

**Author contributions:** Salameh H study design, data collection and interpretation, and drafting and editing manuscript; Masadeh M literature review, data extraction and study quality assessment; Al Hanayneh M literature review, data extraction and study quality assessment; Petros V literature review, drafting and editing the manuscript; Maslonka M literature review, data extraction and study quality assessment; Nanda A drafting and editing the manuscript; Singal A study design, data analysis and interpretation, and manuscript editing. All the authors approved the final version of the manuscript.

**Conflict-of-interest statement:** The authors deny any conflict of interest.

**Data sharing statement**: No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Habeeb M Salameh, MD, CMQ,** Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Texas Medical Branch at Galveston, 301 University Blvd, Galveston, TX 77550, United States. habeeb.salameh@yahoo.com

**Telephone**: +1-409-7721501

**Fax**: +1-409-7724789

**Received:** June 28, 2016

**Peer-review started:** June 28, 2016

**First decision:** August 10, 2016

**Revised:** September 9, 2016

**Accepted:** October 17, 2016

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To examine the association of *Patatin-like phospholipase domain protein 3* (*PNPLA3*) polymorphisms in chronic hepatitis C patients and development of liver disease spectrum.

***METHODS***

Literature was searched systematically from PubMed/Medline, Embase, and Cochrane search engines for full-length articles written in English that examined *PNPLA3* polymorphism in Chronic Hepatitis C (CHC) patients. Studies evaluating the association of *PNPLA3* polymorphism spectrum (fatty liver, steatohepatitis, cirrhosis, and hepatocellular carcinoma) of CHC were included. Pooled data are reported as odds ratio (OR) with 95%CI. Our study endpoint was the risk of the entire liver disease spectrum including: steatosis/fatty liver, cirrhosis, and HCC (Hepatocellular Carcinoma) in CHC patients with *PNPLA 3* polymorphisms.

***RESULTS***

Of 380 studies identified, a total of 53 studies were included for full-text review. 19 on chronic hepatitis C were eligible for analysis. Pooled odds ratios for rs738409 GG compared to CC and CG among patients with fatty liver (FL) was 2.214 (95%CI: 1.719-2.853). Odds ratios among advanced fibrosis/cirrhosis were 1.762 (95%CI: 1.258-2.468). Similar odds ratios among hepatocellular carcinoma patients were 2.002 (95%CI: 1.519-2.639). Pooled odds ratios for rs738409 GG and CG compared to CC among patients with fatty liver were 1.750 (95%CI: 1.542-1.986). Pooled odds ratios for advanced fibrosis/cirrhosis patients were 1.613 (95%CI: 1.211-2.147). All analyses were homogenous and without publication bias except one. The associations were maintained after adjusting for publication bias and heterogeneity.

**CONCLUSION:** *PNPLA3* polymorphisms have strong association with increased risk and severity of the liver disease spectrum in CHC patients.

**Key words:** *PNPLA3* polymorphism; Cirrhosis; rs738409; Hepatitis C virus; Hepatocellular carcinoma

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** *Patatin-like phospholipase domain protein 3* polymorphisms (rs 738409 CG and GG) are associated with increased risk of steatosis, advanced fibrosis, cirrhosis, and hepatocellular carcinoma in chronic hepatitis Cpatients.

Salameh H, Masadeh M, Al Hanayneh M, Petros V, Maslonka M, Nanda A, Singal AK. *PNPLA3* polymorphism increases risk and severity of chronic hepatitis c liver disease.*World J Hepatol* 2016; In press

**INTRODUCTION**

Hepatitis C virus (HCV) infection is one of the most important causes of chronic liver disease in the United States[1]. About 27% of cases of cirrhosis and 25% of hepatocellular carcinoma (HCC) worldwide are secondary to HCV infection[2]. Multiple genetic factors identified within the past few years have been shown to be associated with the predisposition to chronic liver disease and the progression to cirrhosis and HCC[3,4]. The single nucleotide polymorphism (SNP) rs738409 C>G (isoleucine to methionine substitution at position 148, I148M) in the *patatin-like phospholipase domain containing protein 3* (*PNPLA3*) gene has been strongly linked to progression of liver disease in multiple studies, and this association was confirmed in meta-analyses of the spectrum of alcoholic liver disease (ALD)[5] as well as non-alcoholic liver disease (NAFLD)[6-8].

The frequency of hepatic steatosis varies with ethnicity where it was reported as 45%, 33% and 24% in Hispanics, whites and blacks respectively.[9] At the same time the frequencies of the PNPLA3 rs738409[G] allele were 0.49, 0.23, and 0.17 in Hispanics, European Americans and African Americans[10]. In addition, the prevalence of the GG genotype in different races in fact correlates with the rate of non alcoholic fatty liver disease (NAFLD) in each respective population, with nearly half of all Hispanics possessing the allele, who in turn are also most likely to have NAFLD. The same is true of the inverse, with less than one quarter of African Americans having the PNPLA3 rs738409[G] allele, and they are least likely to develop NAFLD compared to Hispanics and Caucasians[9,10].

Given that the association between *PNPLA3 polymorphism* and liver disease spectrum in chronic hepatitis C (CHC) patients has not been consistent, especially for HCC[11,12] and cirrhosis[13,14], we performed this meta-analysis to further examine the association of *PNPLA3* polymorphisms with the predisposition to the entire spectrum of liver disease among patients with CHC.

**MATERIALS AND METHODS**

***Literature Search***

Utilizing the MOOSE (Meta-analysis of Observational Studies in Epidemiology) guidelines, literature was searched from PubMed/Medline, Embase, and Cochrane search engines for full-length articles written in English that examined *PNPLA3* polymorphism in CHC patients[15]. The initial medical subject headings (MeSH) search terms were: “Hepatitis C, Chronic” and “adiponutrin, human”. The search was then expanded using the terms: “rs738409” and “patatin-like phospholipase domain-containing 3 protein”. All databases were searched from their inception date through March 2015. Meeting abstracts from major gastroenterology conferences over the past 3 years were also searched to identify studies that were potentially overlooked in our database search. Articles were selected for full text review based on title and abstract.

***Study Selection***

Three independent investigators (MM, MA, and MM) manually search the retrieved publications to ensure all appropriate articles were discovered and included. Two authors (HS and AKS) reviewed articles in question for possible inclusion. The following inclusion criteria were set for inclusion in this meta-analysis: (1) Studies published as full-length articles which reported association of the *PNPLA3* variant (rs738409 C>G) among CHC patients; and (2) Studies which analyzed patients with other liver diseases and reported separate data on *PNPLA3* polymorphisms for CHC.

The following exclusion criteria were set: (1) Studies without available gene frequency data for analysis; and (2) Studies including subjects with other liver diseases without separate data on CHC patients.

***Definitions***

HCV infection was diagnosed with both positive serum anti-HCV antibodies and serum HCV ribonucleic acid (RNA). The disease spectrum was defined as the following: steatosis = FL on imaging without evidence of cirrhosis or HCC; advanced fibrosis and cirrhosis = biopsy-proven bridging fibrosis, or clinical evaluation supported by hematological, biochemical, and radiologic imaging findings; and HCC = diagnostic imaging findings on triple phase magnetic resonance imaging (MRI) or computed tomography (CT), or using histological confirmation from liver tissue. Healthy controls were defined as subjects without liver disease and without HCV infection.

***Data extraction***

After determining eligibility for inclusion, two reviewers (MM and MA) independently extracted data for (1) study characteristics: author and year of publication, and study design (population based or not, using controls or not); (2) study population: liver disease spectrum and sample size; (3) frequencies of *PNPLA3* polymorphism genotypes (rs738409 CC, CG, and GG); and (4) odds ratios (OR): for association of *PNPLA3* polymorphism and the spectrum of liver disease and for severity of liver disease. Any discrepancies amongst the reviewers were resolved by jointly reviewing the study in question. Among studies comparing diseased population with healthy controls, similar data were also extracted on healthy controls.

***Endpoints and outcomes***

Our study endpoint was the risk of the entire liver disease spectrum including: steatosis/fatty liver, cirrhosis, and HCC in CHC patients with *PNPLA 3* polymorphisms.

***Quality assessment***

The quality of included studies was assessed independently by three authors (MM, MA and MM) using the Newcastle-Ottawa Quality Assessment Scale for case-control studies[16]. This scale has one instrument for assessing case–control studies and another one for cohort studies. Each of these instruments includes measures of quality in selection, comparability, and exposure domains. While one point is granted for each of the areas measured within the selection and exposure domains, a maximum of two points can be assigned within the comparability domain with highest possible total score of nine. Previous studies have reported that a score of seven or greater denotes a high-quality study.[17] Any discrepancies between the three coauthors were addressed by a joint reevaluation of the original article.

***Statistical analysis***

The strength of the association between rs738409 and CHC liver disease spectrum prevalence was expressed by OR and their corresponding 95%CI. The Random effects model was used for analyzing pooled data for all the analyses[18]. Heterogeneity was measured using I2 statistics for inter-study variance, with the chi-square test used for statistical analysis. Heterogeneity was defined with I2 ≥ 50% or χ2 *P* < 0.10[19]. At least two studies are needed to examine and report heterogeneity. To examine the heterogeneous data and source of heterogeneity, sensitivity analyses were performed in a stepwise fashion for (1) study quality; and (2) excluding studies with the highest and lowest OR. Publication bias was assessed using Egger regression and the Begg-Mazumdar rank correlation tests[20-22]. Egger test is a regression method checking for association between effect sizes and standard error and uses actual effect size for each study[22]. Begg-Mazumdar is a rank correlation test examining the potential association between effect estimates (taken as a rank and not exact effect size) and sampling variance (or standard error)[21]. At least three studies are needed for examining and reporting publication bias. For analyses with publication bias, the analyses were repeated either by performing sensitivity analysis or using the Duval and Tweedie Trim and Fill method, a nonparametric (rank-based) data augmentation technique.[23] The method can be used to estimate the number of studies missing from a meta-analysis resulting in a skew of the data due to the suppression of the most extreme results on one side of the funnel plot. The method then amplifies the observed data so that the funnel plot is more symmetric and re-computes the summary estimate based on the comprehensive data. The method should not be regarded as a way of yielding a more "valid" estimate of the overall effect or outcome, but as a means of examining the sensitivity of the results to one particular selection mechanism.[24] All statistical analyses were performed using R (Foundation for Statistical Computing) utilizing the metaphor package, or Comprehensive Meta-analysis (Biostat, Englewood, NJ). Singal AK from University of Alabama, Birmingham, reviewed the statistical methods of this study.

**RESULTS**

***Baseline study characteristics***

A total of 380 citations were retrieved on initial search. After reviewing article titles and abstracts, a total of 53 studies were included for full-text review (Figure 1). Of these, twenty articles were excluded because they did not have sufficient data for our analysis. Nine studies were excluded for including subjects with liver disease not caused by HCV[10,25-32], and three studies were excluded for including subjects co-infected with HIV and/or hepatitis B virus infection[33-35]. One duplicate study[36] and one study that looked at treatment response[37] were excluded. Nineteen studies evaluating 9093 patients (57.6% males, mean body mass index (BMI) 25.1 kg/m2) on association of *PNPLA3* polymorphisms in CHC[11,13,14,38-53] were included for the analysis. Data on study design, ethnicity and genotype frequency are summarized in Table 1.

***Study quality assessment***

Based on the Newcastle-Ottawa Scale, nine studies were of “high quality” with a score of seven or more, and the remaining ten studies had a score of six or below (Table 2).

***Association between PNPLA3 polymorphism and liver disease spectrum (*GG *vs* CG and CC analysis*)***

**Association of *PNPLA3* Polymorphisms with Fatty Liver (FL) in CHC Patients:** Among six studies on 3310 patients, the pooled OR for rs738409 GG genotype compared to CC and CG genotypes in CHC was 2.214 (95%CI: 1.719-2.853) (Figure 2A). The data was homogeneous (I2 = 9.4%, *P* = 0.36) and without publication bias as assessed by Egger test (*P* = 0.08) and Begg-Mazumdar test (*P* = 0.14).

**Association of *PNPLA3* Polymorphisms with Advanced Fibrosis and Cirrhosis in CHC: Patients:** Among seven studies on 3377 patients, the pooled OR for rs738409 GG genotype compared to CC and CG genotypes in CHC was 1.762 (CI: 1.258-2.469) (Figure 2B). The data was heterogeneous (*I*2 = 65.9%, *P* = 0.081), with evidence of publication bias as assessed by Begg-Mazumdar test (*P* = 0.036) and tendency for publication bias as assessed by Egger test (*P* = 0.059). Sensitivity analysis after excluding studies with lowest[13] and highest[49] OR revealed similar effect size: 1.82 (95%CI: 1.41-2.34) with *I*2 = 18.8%, *P* = 0.30. Additionally, when Dual and Tweedie trim and fall test were used to assess publication bias, 3 studies were trimmed with no change in effect size (OR = 1.39, 95%CI: 1.01-1.92).

**Association of *PNPLA3* polymorphisms and HCC in CHC patients**

Among seven studies on 2274 patients, the pooled OR for rs738409 GG genotype compared to CC and CG genotypes in CHC was 2.002 (95%CI: 1.519-2.639) (Figure 2C). The data was homogenous (*I*2 = 30%, *P* = 0.19), without publication bias as assessed by Egger test (*P* = 0.91) and Begg-Mazumdar test (*P* = 0.99).

**Association of *PNPLA3* polymorphisms with FL in CHC patients:** Among three studies on 1,794 patients, the pooled OR for rs738409 GG and CG genotypes compared to CC genotype in CHC was 1.750 (95%CI: 1.542-1.986) (Figure 3A). The data was homogeneous (*I*2 = 0.0%, *P* = 0.84), without publication bias as assessed by Egger test (*P* = 0.57) and Begg-Mazumdar test (*P* = 0.99).

**Association of *PNPLA3* polymorphisms with advanced fibrosis, and cirrhosis in CHC patients:** Among three studies on 2131 patients, the pooled OR for rs738409 GG and CG genotypes compared to CC genotype in CHC was 1.613 (95%CI: 1.211-2.147) (Figure 3B). The data was homogeneous (*I*2 = 41%, *P* = 0.18), without publication bias as assessed by Egger test (*P* = 0.056) and Begg-Mazumdar test (*P* = 0.99).

**DISCUSSION**

We have previously described that *PNPLA3* polymorphism is a modifier in the natural history of ALD[5] and non-alcoholic fatty liver disease (NAFLD)[6-8]. In this meta-analysis, we found a clear association between *PNPLA3* polymorphisms and the entire spectrum (steatosis/fatty liver, cirrhosis, and HCC) of liver disease in CHC patients.

It was previously reported that *PNPLA3* polymorphisms were an independent predictor of more rapid fibrosis progression in patients with chronic hepatitis C[50]. The mechanism whereby rs738409 influences the development of fatty liver likely involves a decreased ability of the 148M *PNPLA3* variant to regulate hepatic lipid metabolism[54]. It is not known whether the rs738409 SNP influences the steatogenic effect of HCV and the progression of CHC. However, if steatosis causes fibrosis progression in CHC, then it may be assumed the rs738409 SNP should also be associated with advanced fibrosis and HCC[39].

Like any other meta-analysis, our study had to face the possibility of publication bias. In order to minimize this possibility, and the subsequent overestimation of the true effect size due to negative study identification failure[55], we combined searches from PubMed/Medline, Embase and Cochrane with manual searches. Although we used procedures in agreement with current guidelines, we cannot formally rule out the possibility that we overlooked studies that were not accessible[55]. Another limitation of this meta-analysis is the inclusion of case-control studies in which the potential for biases (*e.g.,* selection and reporting) is higher when compared to randomized trials, and they are more inherent to confounding factors. In contrary to the previous meta-analysis on *PNPLA3* polymorphisms in alcoholic and non-alcoholic liver diseases that compared different genotypes[5-8], our current analysis used the recessive model when comparing GG genotype *vs* CC and CG genotypes, and the dominant model when comparing GG and CG genotypes related to the CC genotype. Finally, no pooled data were provided on steatohepatitis in chronic HCV patients as only one study had reported such an association[13], while the studies by Ezzikouri *et al[44]* and Yasui *et al[48]* either did not have biopsies performed or reported “necroinflammatory changes”. Lack of standard definition amongst these studies prevented pooling them together.

The *PNPLA3* GG genotype was negatively associated with sustained virological response and early viral kinetics in patients receiving peginterferon and ribavirin[14]. Also, in patients with chronic hepatitis C who failed to achieve sustained virologic response following interferon-based therapy, IL28B and *PNPLA3* were independent predictors of rapid fibrosis progression[50]. Tamaki *et al*[50] developed a fibrosis progression-score by combining IL28B and *PNPLA3* genotypes and ALT values, which stratified patients into low, intermediate, and high-risk groups for fibrosis progression. However, this fibrosis progression score needs external validation. In the era of direct-acting antiviral therapy, the question that remains unanswered is whether or not *PNPLA3* polymorphisms identify high-risk CHC patients that are responsive to new treatment regimens. In summary, this meta-analysis provides strong evidence for the association of *PNPLA3* polymorphisms and the spectrum of liver disease in patients with CHC, beginning with fatty liver disease and extending as far as cirrhosis and even HCC in patients with CHC. Further studies on treatment response are needed in this group of patients who carry a higher risk for more rapidly progressive liver disease.

**COMMENTS**

***Background***

Hepatitis C virus (HCV) infection is one of the most important causes of chronic liver disease in the United States. About 27% of cases of cirrhosis and 25% of hepatocellular carcinoma (HCC) worldwide are secondary to HCV infection.

***Research frontiers***

Given that the association between *PNPLA3 polymorphism* and liver disease spectrum in chronic hepatitis C (CHC) patients has not been consistent, especially for HCC and cirrhosis, the authors performed this meta-analysis to further examine the association of *PNPLA3* polymorphisms with the predisposition to the entire spectrum of liver disease among patients with CHC.

***Innovations and breakthroughs***

In this meta-analysis, they found a clear association between *PNPLA3* polymorphisms and the entire spectrum (steatosis/fatty liver, cirrhosis, and HCC) of liver disease in CHC patients.

***Peer-review***

This manuscript is very well designed, the authors did a great effort in selecting the articles to be included in the meta-analysis with a proper quality scoring of selected articles.

**REFERENCES**

1 **Younossi ZM**, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. *Clin Gastroenterol Hepatol* 2011; **9**: 524-530.e1; quiz e60 [PMID: 21440669 DOI: 10.1016/j.cgh.2011.03.020]

2 **Alter MJ**. Epidemiology of hepatitis C virus infection. *World J Gastroenterol* 2007; **13**: 2436-2441 [PMID: 17552026 DOI: 10.3748/wjg.v13.i17.2436]

3 **Labib HA**, Ahmed HS, Shalaby SM, Wahab EA, Hamed EF. Genetic polymorphism of IL-23R influences susceptibility to HCV-related hepatocellular carcinoma. *Cell Immunol* 2015; **294**: 21-24 [PMID: 25666505 DOI: 10.1016/j.cellimm.2015.01.012]

4 **Singal AG**, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P, Waljee AK. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. *Am J Gastroenterol* 2014; **109**: 325-334 [PMID: 24445574 DOI: 10.1038/ajg.2013.476]

5 **Salameh H**, Raff E, Erwin A, Seth D, Nischalke HD, Falleti E, Burza MA, Leathert J, Romeo S, Molinaro A, Corradini SG, Toniutto P, Spengler U, Daly A, Day CP, Kuo YF, Singal AK. PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease. *Am J Gastroenterol* 2015; **110**: 846-856 [PMID: 25964223 DOI: 10.1038/ajg.2015.137]

6 **Sookoian S**, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. *Hepatology* 2011; **53**: 1883-1894 [PMID: 21381068 DOI: 10.1002/hep.24283]

7 **Xu R**, Tao A, Zhang S, Deng Y, Chen G. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis. *Sci Rep* 2015; **5**: 9284 [PMID: 25791171 DOI: 10.1038/srep09284]

8 **Zhang L**, You W, Zhang H, Peng R, Zhu Q, Yao A, Li X, Zhou Y, Wang X, Pu L, Wu J. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis. *J Gastroenterol Hepatol* 2015; **30**: 821-829 [PMID: 25641744 DOI: 10.1111/jgh.12889]

9 **Browning JD**, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004; **40**: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]

10 **Romeo S**, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2008; **40**: 1461-1465 [PMID: 18820647 DOI: 10.1038/ng.257]

11 **Guyot E**, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, Ganne-Carrié N, Beaugrand M, Charnaux N, Trinchet JC, Nahon P. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. *J Hepatol* 2013; **58**: 312-318 [PMID: 23069476 DOI: 10.1016/j.jhep.2012.09.036]

12 **Nischalke HD**, Berger C, Luda C, Berg T, Müller T, Grünhage F, Lammert F, Coenen M, Krämer B, Körner C, Vidovic N, Oldenburg J, Nattermann J, Sauerbruch T, Spengler U. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. *PLoS One* 2011; **6**: e27087 [PMID: 22087248 DOI: 10.1371/journal.pone.0027087]

13 **Petta S**, Vanni E, Bugianesi E, Rosso C, Cabibi D, Cammà C, Di Marco V, Eslam M, Grimaudo S, Macaluso FS, McLeod D, Pipitone RM, Abate ML, Smedile A, George J, Craxì A. PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. *Aliment Pharmacol Ther* 2015; **41**: 939-948 [PMID: 25801076 DOI: 10.1111/apt.13169]

14 **Valenti L**, Aghemo A, Stättermayer AF, Maggioni P, De Nicola S, Motta BM, Rumi MG, Dongiovanni P, Ferenci P, Colombo M, Fargion S. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. *Aliment Pharmacol Ther* 2012; **35**: 1434-1442 [PMID: 22530607 DOI: 10.1111/j.1365-2036.2012.05109.x]

15 **Stroup DF**, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000; **283**: 2008-2012 [PMID: 10789670]

16 **Wells GA**, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: URL: http://www.ohri.ca/programs/clinical\_epidemiology/oxford.asp

17 **Ungaro R**, Bernstein CN, Gearry R, Hviid A, Kolho KL, Kronman MP, Shaw S, Van Kruiningen H, Colombel JF, Atreja A. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. *Am J Gastroenterol* 2014; **109**: 1728-1738 [PMID: 25223575 DOI: 10.1038/ajg.2014.246]

18 **DerSimonian R**, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**: 177-188 [PMID: 3802833]

19 **Higgins JP**, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**: 557-560 [PMID: 12958120 DOI: 10.1136/bmj.327.7414.557]

20 **Deeks JJ,** Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M DSG, Altman DG, eds, editor Systematic Reviews in Health Care: Meta- Analysis in Context. 2nd edition ed. London: BMJ Books, 2005: 285-312

21 **Begg CB**, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994; **50**: 1088-1101 [PMID: 7786990 DOI: 10.2307/2533446]

22 **Egger M**, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; **315**: 629-634 [PMID: 9310563 DOI: 10.1136/bmj.315.7109.629]

23 **Duval S**, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000; **56**: 455-463 [PMID: 10877304 DOI: 10.1111/j.0006-341X.2000.00455.x]

24 Trim and Fill Analysis for 'rma.uni' Objects. Available from: URL: http://handbook.cochrane.org/chapter\_10/10\_4\_4\_2\_trim\_and\_fill.htm

25 **Hamza S,** Petit JM, Masson D, Jooste V, Binquet C, Sgro C, Guiu B, Bronowicki JP, Thieffin G, Di Martino V, Doffoel M, Barraud H, Richou C, Jouve JL, Raab JJ, Bouvier AM, Cottet V, Verges B, Minello A, Bonithon Kopp C, Hillon P. PNPLA3 rs738409 GG homozygote status is associated with increased risk of hepatocellular carcinoma in cirrhotic patients. *J Hepatol* 2012: S281–S282 [DOI: 10.1016/S0168-8278(12)60725-9]

26 **Way M,** McQuillin A, Gurling HMD, Morgan MY. The PNPLA3 I148M mutation significantly increases the risk of developing alcohol-related cirrhosis in alcohol-dependent individuals. *J Hepatol* 2013; **58**: S563–S564 [DOI: 10.1016/S0168-8278(13)61403-8]

27 **Dutta AK**. Genetic factors affecting susceptibility to alcoholic liver disease in an Indian population. *Ann Hepatol* 2013; **12**: 901-907 [PMID: 24114820]

28 **Nguyen-Khac E**, Houchi H, Dreher M-L, Herpe Y-E, Naassila M. Is PNPLA3 polymorphism involved in severe acute alcoholic hepatitis. *Hepatology* 2011: 976A

29 **Bhatt SP**, Nigam P, Misra A, Guleria R, Pandey RM, Pasha MA. Genetic variation in the patatin-like phospholipase domain-containing protein-3 (PNPLA-3) gene in Asian Indians with nonalcoholic fatty liver disease. *Metab Syndr Relat Disord* 2013; **11**: 329-335 [PMID: 23734760 DOI: 10.1089/met.2012.0064]

30 **Burza MA**, Pirazzi C, Maglio C, Sjöholm K, Mancina RM, Svensson PA, Jacobson P, Adiels M, Baroni MG, Borén J, Ginanni Corradini S, Montalcini T, Sjöström L, Carlsson LM, Romeo S. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. *Dig Liver Dis* 2012; **44**: 1037-1041 [PMID: 22704398 DOI: 10.1016/j.dld.2012.05.006]

31 **Kotronen A**, Johansson LE, Johansson LM, Roos C, Westerbacka J, Hamsten A, Bergholm R, Arkkila P, Arola J, Kiviluoto T, Fisher RM, Ehrenborg E, Orho-Melander M, Ridderstråle M, Groop L, Yki-Järvinen H. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. *Diabetologia* 2009; **52**: 1056-1060 [PMID: 19224197 DOI: 10.1007/s00125-009-1285-z]

32 **Santoro N**, Kursawe R, D'Adamo E, Dykas DJ, Zhang CK, Bale AE, Calí AM, Narayan D, Shaw MM, Pierpont B, Savoye M, Lartaud D, Eldrich S, Cushman SW, Zhao H, Shulman GI, Caprio S. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. *Hepatology* 2010; **52**: 1281-1290 [PMID: 20803499 DOI: 10.1002/hep.23832]

33 **Zampino R**, Pisaturo MA, Cirillo G, Marrone A, Macera M, Rinaldi L, Stanzione M, Durante-Mangoni E, Gentile I, Sagnelli E, Signoriello G, Miraglia Del Giudice E, Adinolfi LE, Coppola N. Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. *Ann Hepatol* 2015; **14**: 75-82 [PMID: 25536644]

34 **Morse CG**, McLaughlin M, Matthews L, Proschan M, Thomas F, Gharib AM, Abu-Asab M, Orenstein A, Engle RE, Hu X, Lempicki R, Hadigan C, Kleiner DE, Heller T, Kovacs JA. Nonalcoholic Steatohepatitis and Hepatic Fibrosis in HIV-1-Monoinfected Adults With Elevated Aminotransferase Levels on Antiretroviral Therapy. *Clin Infect Dis* 2015; **60**: 1569-1578 [PMID: 25681381 DOI: 10.1093/cid/civ101]

35 **Mandorfer M**, Payer BA, Schwabl P, Steiner S, Ferlitsch A, Aichelburg MC, Stättermayer AF, Ferenci P, Obermayer-Pietsch B, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T. Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. *Liver Int* 2015; **35**: 876-885 [PMID: 24905495 DOI: 10.1111/liv.12615]

36 **Huang CF**, Dai CY, Yeh ML, Huang CI, Tai CM, Hsieh MH, Liang PC, Lin YH, Hsieh MY, Yang HL, Huang JF, Lin ZY, Chen SC, Yu ML, Chuang WL. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. *J Hepatol* 2015; **62**: 512-518 [PMID: 25457210 DOI: 10.1016/j.jhep.2014.10.011]

37 **Wong GL**, Chan HL, Tse CH, Chan PO, Cheng JC, Cheng JS, Lau SH, Lee EK, Ma JM, Chan AW, Choi PC, Wong VW. Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus. *J Gastroenterol Hepatol* 2015; **30**: 1040-1048 [PMID: 25639146 DOI: 10.1111/jgh.12890]

38 **Cai T**, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Moradpour D, Cerny A, Malinverni R, Kaddai V, Bochud M, Negro F, Bochud PY. Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. *J Hepatol* 2011; **55**: 529-535 [PMID: 21236304 DOI: 10.1016/j.jhep.2010.12.020]

39 **Valenti L**, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, Colombo M, Fargion S. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. *Hepatology* 2011; **53**: 791-799 [PMID: 21319195 DOI: 10.1002/hep.24123]

40 **Trépo E**, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, Lemmers A, Berthillon P, Amininejad L, Chevallier M, Schlué J, Kreipe H, Devière J, Manns M, Trépo C, Sninsky J, Wedemeyer H, Franchimont D, Moreno C. Impact of patatin-like phospholipase-3 (rs738409 C& gt; G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. *Hepatology* 2011; **54**: 60-69 [PMID: 21488075 DOI: 10.1002/hep.24350]

41 **Corradini SG**, Burza MA, Molinaro A, Romeo S. Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. *Hepatology* 2011; **53**: 1776; author reply 1777 [PMID: 21351112 DOI: 10.1002/hep.24244]

43 **Valenti L**, Aghemo A, Stättermayer AF. Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. *J Hepatol* 2012; **56**: 1209-110; author reply 1209-110; [PMID: 22230871 DOI: 10.1016/j.jhep.2011.10.024]

44 **Ezzikouri S**, Alaoui R, Tazi S, Nadir S, Elmdaghri N, Pineau P, Benjelloun S. The adiponutrin I148M variant is a risk factor for HCV-associated liver cancer in North-African patients. *Infect Genet Evol* 2014; **21**: 179-183 [PMID: 24269995 DOI: 10.1016/j.meegid.2013.11.005]

45 **Stättermayer AF**, Rutter K, Beinhardt S, Wrba F, Scherzer TM, Strasser M, Hofer H, Steindl-Munda P, Trauner M, Ferenci P. Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C. *Liver Int* 2014; **34**: 388-395 [PMID: 23870067 DOI: 10.1111/liv.12269]

46 **Ampuero J**, Del Campo JA, Rojas L, García-Lozano JR, Solá R, Andrade R, Pons JA, Navarro JM, Calleja JL, Buti M, González-Escribano MF, Forns X, Diago M, García-Samaniego J, Romero-Gómez M. PNPLA3 rs738409 causes steatosis according to viral & amp; IL28B genotypes in hepatitis C. *Ann Hepatol* 2014; **13**: 356-363 [PMID: 24927606]

47 **Sato M**, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K. Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. *Hepatol Res* 2014; **44**: E137-E144 [PMID: 24125181 DOI: 10.1111/hepr.12258]

48 **Yasui K**, Kawaguchi T, Shima T, Mitsuyoshi H, Seki K, Sendo R, Mizuno M, Itoh Y, Matsuda F, Okanoue T. Effect of PNPLA3 rs738409 variant (I148 M) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C. *J Gastroenterol* 2015; **50**: 887-893 [PMID: 25543233 DOI: 10.1007/s00535-014-1018-z]

49 **Nakaoka K**, Hashimoto S, Kawabe N, Nitta Y, Murao M, Nakano T, Shimazaki H, Kan T, Takagawa Y, Ohki M, Kurashita T, Takamura T, Nishikawa T, Ichino N, Osakabe K, Yoshioka K. PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients. *Springerplus* 2015; **4**: 83 [PMID: 25713769 DOI: 10.1186/s40064-015-0870-5]

50 **Tamaki N**, Kurosaki M, Higuchi M, Takada H, Nakakuki N, Yasui Y, Suzuki S, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Ogawa S, Tanaka Y, Asahina Y, Izumi N. Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. *PLoS One* 2015; **10**: e0137351 [PMID: 26352693 DOI: 10.1371/journal.pone.0137351]

51 **Huang CF**, Chen JJ, Yeh ML, Huang CI, Hsieh MY, Yang HL, Dai CY, Huang JF, Lin ZY, Chen SC, Chuang WL, Chen YL, Yu ML. PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. *Sci Rep* 2015; **5**: 11901 [PMID: 26139292 DOI: 10.1038/srep11901]

52 **Petta S**, Maida M, Grimaudo S, Pipitone RM, Macaluso FS, Cabibi D, Cammà C, Di Marco V, Sferrazza S, Craxì A. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. *Liver Int* 2016; **36**: 198-204 [PMID: 26259026 DOI: 10.1111/liv.12918]

53 **Ali M**, Yopp A, Gopal P, Beg MS, Zhu H, Lee W, Singal AG. A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection. *Clin Gastroenterol Hepatol* 2016; **14**: 295-300 [PMID: 26305067 DOI: 10.1016/j.cgh.2015.08.018]

54 **He S**, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, Cohen JC, Hobbs HH. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. *J Biol Chem* 2010; **285**: 6706-6715 [PMID: 20034933 DOI: 10.1074/jbc.M109.064501]

55 **Thornton A**, Lee P. Publication bias in meta-analysis: its causes and consequences. *J Clin Epidemiol* 2000; **53**: 207-216 [PMID: 10729693 DOI: 10.1016/S0895-4356(99)00161-4]

**P-Reviewer:** Kohla MAS, Pekgoz M, Yang SS **S-Editor:** Qi Y **L-Editor: E-Editor:**

Table 1 Baseline characteristics of patients from studies included in the analysis

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ref. | Study Design | Controls (*n*) | Cases | | | | | | | | |
| ***n*** | **Ethnicity** | **M%** | **Mean Age** | **Mean BMI** | **rs 738409 genotype count (CC:CG:GG)*4*** | | | |
| **FL** | **Hepatitis** | **Cirrhosis** | **HCC** |
| Cai *et al*[38] (2011) | R | - | 626 | C | 61.8 | 44.7 | 23.7 | 62:28**1** | - | - | - |
| Valenti *et al*[39] (2011) | R | 179 | 819 | C+NA | 56.4 | 57.4 | 24.8 | 269:219:73 | - | 119:172:229 | 17:21:12 |
| Trepo *et al*[40] (2011) | R | - | 537 | C | 63 | 49.4 | 25.5 | 136:106:31 | - | 108:85:23 | - |
| Corradini *et al*[41] (2011) | P6 | - | 221 | C | 63 | 58 | - | - | - | - | - |
| Nischalke *et al*[12] (2011) | P | 190 | 162 | C | 57 | 56 | 28.4 | - | - | 45:31:05 | 40:33:08 |
| Valenti *et al* (2012) | P | - | 567 | NS | - | - | - | - | - | - | - |
| Valenti *et al*[14] (2012) | P6 | - | 602 | NS | 51 | 51 | 25.1 | 364 : 42**2** | - | 158 : 21**2** | - |
| Guyot *et al*[11] (2013) | P | - | 253 | NS | 54.2 | 56.7 | 27.3 | - | - | 140:75:38 | 54:26:13 |
| Ezzikouri *et al*[44] (2013) | P | 132 | 230 | NA | 45.2 | 63.63 | - | - | 47:71:11 | - | 43:35:23 |
| Stattermayer *et al*[45] (2014) | R | - | 478 | NS | 65.7 | 44.9 | 25.6 | 190 : 23**2** | - | 101 : 57**2** | - |
| Ampuero *et al*[46] (2014) | P6 | - | 474 | M | 64.8 | 43.4 | 25.7 | 94:126**3** | - | - | - |
| Sato *et al*[47] (2014) | R | - | 358 | A | 55.9 | 69.76 | - | 41 : 20**2** | - | 112 : 37**2** | 100:176:82 |
| Yasui *et al*[48] (2014) | P6 | - | 276 | A | 40.6 | 58.2 | 23 | 23:75:039 | 45:66:038 | 20:31:021 | - |
| Petta *et al*[13] (2015) | P | - | 434 | C | 53.9 | 51.7 | - | - | 40:35:12 | 71:36:13 | - |
| Nakaoka *et al*[49] (2015 ) | P | - | 231 | A | 44.6 | 62.9 | 22.5 | - | - | 90 : 27**2** | 12:22:14 |
| Tamaki *et al*[50] (2015) | R | - | 176 | A | 39.8 | 56.5 | 22.9 | - | - | 52:87:37 | - |
| Huang *et al*[51] (2015) | R | - | 1018 | A | 56.6 | 51.8 | 24.9 | 175:205:75 | - | - | - |
| Petta *et al*[52] (2016) | P6 | - | 694 | C | 53 | 54 | 26.5 | 151:151:455 | - | - | - |
| Ali *et al*[53] (2016) | P | - | 937 | M | 70.1 | 49.5 | - | - | - | 172:212**3** | - |
| Summary | | 501 | 9093 |  | 57.6 | 52.7 | 25.1 |  |  |  |  |

1C allele: G allele; 2CC + CG: GG, and 3CC: CG + GG; 4Genotype counts were reported as ratios (CC wild genotype: CG heterozygote genotype: GG homozygote genotype) unless indicated by star(s); 5Calculated from percentages in the original article; 6Population based studies. A: Asian; BMI: Body mass index; C: Caucasian; FL: Fatty liver; HCC: Hepatocellular carcinoma; M: Males; N: Number of cases; NA: North African; NS: Not specified in the original manuscripts (although all 4 studies included European referral centers only); Mixed [Caucasians and non-Caucasians[46] and White/Black/Hispanic[53]; P: Prospective; R: Retrospective.

Table 2 Newcastle -Ottawa Scale on quality score of the included studies

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author (yr)[ref] | Selection | | | | Comparability | | Exposure | | |  | Total |
| **Independent validation** | **Case**  **representation** | **Controls selection** | **Controls definition** | **Case and control design/analysis** | | **Ascertainment of exposure** | **Same method of ascertainment** | **Same response rate** | |
| Cai *et al*[38] (2011) | \* | **\*** |  |  | \*\* | | \* | \* | \* | | **7** |
| Valenti *et al*[39] (2011) | \* | **\*** | **\*** | \* | \*\* | | \* | \* | \* | | **9** |
| Trepo *et al*[40] (2011) | \* | \* |  |  | \*\* | | \* |  |  | | **5** |
| Corradini *et al*[41] (2011) | \* | \* |  |  | \*\* | | \* |  |  | | **5** |
| Nischalke *et al*[12] (2011) | \* | \* | \* | \* | \*\* | | \* | \* | \* | | **9** |
| Valenti *et al* (2012) | \* | \* |  |  | \*\* | | \* | \* |  | | **6** |
| Valenti *et al*[14] (2012) | \* | \* |  |  | \*\* | | \* | \* |  | | **6** |
| Guyot *et al*[11] (2013) | \* | \* |  |  | \*\* | | \* |  |  | | **5** |
| Ezzikouri *et al*[44] (2013) | \* | \* | \* | \* | \*\* | | \* | \* | \* | | **9** |
| Stattermayer *et al*[45] (2014) | \* | \* |  |  | \*\* | | \* |  |  | | **5** |
| Ampuero *et al*[46] (2014) | \* | **\*** |  |  | \*\* | | \* | \* | \* | | **7** |
| Sato *et al*[47] (2014) | \* | \* |  |  | | \*\* | \* |  |  | | **5** |
| Yasui *et al*[48] (2014) | \* | \* |  |  | | \*\* | \* |  |  | | **5** |
| Petta *et al*[13] (2015) | \* | \* |  |  | | \*\* | \* |  |  | | **5** |
| Nakaoka *et al*[49] (2015 ) | \* | **\*** |  |  | | \*\* | \* |  |  | | **5** |
| Tamaki *et al*[50] (2015) | \* | **\*** |  |  | | \*\* | \* | \* | \* | | **7** |
| Huang *et al*[51] (2015) | \* | **\*** |  |  | | \*\* | \* | \* | \* | | **7** |
| Petta *et al*[52] (2016) | \* | **\*** |  |  | | \*\* | \* | \* | \* | | **7** |
| Ali *et al*[53] (2016) | \* | **\*** |  |  | | \*\* | \* | \* | \* | | **7** |




Figure 1 Attrition on literature search and study inclusion.




Figure 2 Forest plots for analysis of chronic hepatitis C studies on the association of *PNPLA3* polymorphisms GG *vs* CG and CC with fatty liver in (A), cirrhosis in (B), and HCC in (C). The effect size is reported as odds ratio with 95%CI. The bottom line in “the statistics for each study” heading is the pooled effect size analyzed using the random effects model. OR greater than 1 denotes risk for the respective outcome or positive association, and OR less than 1 indicates a protective effect or negative association. The 95%CI not crossing 1 indicates a significant association. While *Valenti et al*[43] in panel (A) refers to reference[43]*, Valenti et al*[14] in panel (B).




Figure 3 Forest plots for analysis of chronic hepatitis C studies on the association of PNPLA3 polymorphisms GG and CG *vs* CC with fatty liver in (A), and cirrhosis in (B). The effect size is reported as odds ratio with 95%CI. The bottom line in the “statistics for each study” heading is the pooled effect size analyzed using the random effects model. OR greater than 1 denotes risk for the respective outcome or positive association, and OR less than 1 indicates a protective effect or negative association. The 95%CI not crossing 1 indicates a significant association.